Please try another search
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. The company’s lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson’s disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer’s disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.
Name | Age | Since | Title |
---|---|---|---|
Colin Louis Masters | 76 | 1999 | Member of Research & Development Advisory Board |
Geoffrey Paul Kempler | 68 | 1997 | Co-Founder & Non-Executive Chairman |
Ira Shoulson | 77 | 2014 | Chairman of Research & Development Advisory Board |
Rudolph Emile Tanzi | 64 | 2007 | Chief Scientific Advisor and Member of Research & Development Advisory Board |
Lawrence B. Gozlan | 44 | 2011 | Non-Executive Director |
Peter Ashley Marks | 67 | 2005 | Non-Executive Independent Director |
Brian Derek Meltzer | 69 | 1999 | Non-Executive Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review